Prokidney (PROK) Cash & Equivalents (2021 - 2026)

Prokidney (PROK) has 6 years of Cash & Equivalents data on file, last reported at $101.9 million in Q1 2026.

• On a quarterly basis, Cash & Equivalents rose 4.18% year-over-year to $101.9 million in Q1 2026; TTM through Mar 2026 was $101.9 million, a 4.18% increase from a year earlier, with the FY2025 full-year figure at $108.5 million, up 9.5% from the prior year.
• Cash & Equivalents for Q1 2026 stood at $101.9 million, down from $108.5 million in the prior quarter.
• Over the last five years, Cash & Equivalents for PROK reached as high as $506.3 million in Q3 2022 and fell as low as $60.6 million in Q4 2023.
• Historically, Cash & Equivalents has averaged $183.9 million across 5 years, with a median of $108.1 million in 2024.
• Across the five-year window, Cash & Equivalents jumped 2284.73% in 2022 and tumbled 87.63% in 2023, its largest moves.
• Year by year, Cash & Equivalents stood at $490.3 million in 2022, then tumbled by 87.63% to $60.6 million in 2023, then surged by 63.43% to $99.1 million in 2024, then advanced by 9.5% to $108.5 million in 2025, then decreased by 6.12% to $101.9 million in 2026.
• Per Business Quant data, the three most recent Cash & Equivalents figures were $101.9 million in Q1 2026, $108.5 million in Q4 2025, and $95.3 million in Q3 2025.